Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53.

Fecteau JF, Corral LG, Ghia EM, Gaidarova S, Futalan D, Bharati IS, Cathers B, Schwaederlé M, Cui B, Lopez-Girona A, Messmer D, Kipps TJ.

Blood. 2014 Sep 4;124(10):1637-44. doi: 10.1182/blood-2014-03-559591. Epub 2014 Jul 2.

2.

Lenalidomide, an antiproliferative CLL drug.

Seiffert M.

Blood. 2014 Sep 4;124(10):1545-6. doi: 10.1182/blood-2014-07-587360. No abstract available.

3.

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, Ford R Jr, Rader C, Muthusamy N, Johnson AJ, Byrd JC.

Blood. 2010 Apr 1;115(13):2619-29. doi: 10.1182/blood-2009-09-242438. Epub 2009 Nov 24.

4.

CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.

Dicker F, Kater AP, Prada CE, Fukuda T, Castro JE, Sun G, Wang JY, Kipps TJ.

Blood. 2006 Nov 15;108(10):3450-7. Epub 2006 Jun 1.

5.
6.

Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.

Acebes-Huerta A, Huergo-Zapico L, Gonzalez-Rodriguez AP, Fernandez-Guizan A, Payer AR, López-Soto A, Gonzalez S.

Biomed Res Int. 2014;2014:265840. doi: 10.1155/2014/265840. Epub 2014 Sep 17.

7.

1,25-Dihydroxyvitamin D3 induces differentiation of a retinoic acid-resistant acute promyelocytic leukemia cell line (UF-1) associated with expression of p21(WAF1/CIP1) and p27(KIP1).

Muto A, Kizaki M, Yamato K, Kawai Y, Kamata-Matsushita M, Ueno H, Ohguchi M, Nishihara T, Koeffler HP, Ikeda Y.

Blood. 1999 Apr 1;93(7):2225-33.

8.

Alterations in TP53, cyclin D2, c-Myc, p21WAF1/CIP1 and p27KIP1 expression associated with progression in B-CLL.

Halina A, Artur P, Barbara MK, Joanna S, Anna D.

Folia Histochem Cytobiol. 2010 Dec;48(4):534-41. doi: 10.2478/v10042-010-0048-5.

9.

Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.

Fiorcari S, Martinelli S, Bulgarelli J, Audrito V, Zucchini P, Colaci E, Potenza L, Narni F, Luppi M, Deaglio S, Marasca R, Maffei R.

Haematologica. 2015 Feb;100(2):253-62. doi: 10.3324/haematol.2014.113217. Epub 2014 Nov 14.

10.

Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia.

Cobo F, Martínez A, Pinyol M, Hernández L, Gómez M, Beá S, Esteve J, Rozman M, Bosch F, López-Guillermo A, Montserrat E, Campo E.

Leukemia. 2002 Jun;16(6):1028-34.

11.

Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer.

Yu SY, Liao CH, Chien MH, Tsai TY, Lin JK, Weng MS.

J Agric Food Chem. 2014 Mar 5;62(9):2085-95. doi: 10.1021/jf4037722. Epub 2014 Feb 24.

PMID:
24533688
12.

LYG-202 inhibits the proliferation of human colorectal carcinoma HCT-116 cells through induction of G1/S cell cycle arrest and apoptosis via p53 and p21(WAF1/Cip1) expression.

Liu W, Dai Q, Lu N, Wei L, Ha J, Rong J, Mu R, You Q, Li Z, Guo Q.

Biochem Cell Biol. 2011 Jun;89(3):287-98. doi: 10.1139/O10-162. Epub 2011 Apr 14.

PMID:
21491996
13.

The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21 pathway.

Agnoletto C, Brunelli L, Melloni E, Pastorelli R, Casciano F, Rimondi E, Rigolin GM, Cuneo A, Secchiero P, Zauli G.

Oncotarget. 2015 Feb 10;6(4):2385-96.

14.

Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner.

Masood A, Chitta K, Paulus A, Khan AN, Sher T, Ersing N, Miller KC, Manfredi D, Ailawadhi S, Borrelo I, Lee KP, Chanan-Khan A.

Br J Haematol. 2012 Apr;157(1):59-66. doi: 10.1111/j.1365-2141.2011.08984.x. Epub 2011 Dec 15.

PMID:
22171982
15.

Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.

Maffei R, Fiorcari S, Bulgarelli J, Rizzotto L, Martinelli S, Rigolin GM, Debbia G, Castelli I, Bonacorsi G, Santachiara R, Forconi F, Rossi D, Laurenti L, Palumbo GA, Vallisa D, Cuneo A, Gaidano G, Luppi M, Marasca R.

Exp Hematol. 2014 Feb;42(2):126-36.e1. doi: 10.1016/j.exphem.2013.10.007. Epub 2013 Nov 6.

PMID:
24212063
16.

Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment.

Schulz A, Dürr C, Zenz T, Döhner H, Stilgenbauer S, Lichter P, Seiffert M.

Blood. 2013 Mar 28;121(13):2503-11. doi: 10.1182/blood-2012-08-447664. Epub 2013 Jan 24.

17.

p53-independent expression of p21(CIP1/WAF1) in plasmacytic cells during G(2) cell cycle arrest induced by Actinobacillus actinomycetemcomitans cytolethal distending toxin.

Sato T, Koseki T, Yamato K, Saiki K, Konishi K, Yoshikawa M, Ishikawa I, Nishihara T.

Infect Immun. 2002 Feb;70(2):528-34.

19.

p21 Waf1/Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression.

Choi BH, Kim CG, Bae YS, Lim Y, Lee YH, Shin SY.

Cancer Res. 2008 Mar 1;68(5):1369-77. doi: 10.1158/0008-5472.CAN-07-5222.

20.
Items per page

Supplemental Content

Write to the Help Desk